Saturday, August 22, 2009

Tridemin




Tridemin may be available in the countries listed below.


Ingredient matches for Tridemin



Ubidecarenone

Ubidecarenone is reported as an ingredient of Tridemin in the following countries:


  • Japan

International Drug Name Search

Posted by at No comments:
Labels:

Thursday, August 6, 2009

Pravagamma




Pravagamma may be available in the countries listed below.


Ingredient matches for Pravagamma



Pravastatin

Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Pravagamma in the following countries:


  • Germany

International Drug Name Search

Posted by at No comments:
Labels:

Derbicil




Derbicil may be available in the countries listed below.


Ingredient matches for Derbicil



Terbinafine

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Derbicil in the following countries:


  • Bangladesh

International Drug Name Search

Posted by at No comments:
Labels:

Tuesday, August 4, 2009

Ecee2




Ecee2 may be available in the countries listed below.


Ingredient matches for Ecee2



Levonorgestrel

Levonorgestrel is reported as an ingredient of Ecee2 in the following countries:


  • India

  • Myanmar

  • Vietnam

International Drug Name Search

Posted by at No comments:
Labels:

Rebetol


Rebetol is a brand name of ribavirin, approved by the FDA in the following formulation(s):


REBETOL (ribavirin - capsule; oral)



  • Manufacturer: SCHERING PLOUGH RES

    Approval date: June 3, 1998

    Strength(s): 200MG [RLD]


  • Manufacturer: SCHERING PLOUGH RES

    Approval date: July 25, 2001

    Strength(s): 200MG [RLD][AB]

REBETOL (ribavirin - solution; oral)



  • Manufacturer: SCHERING

    Approval date: July 29, 2003

    Strength(s): 40MG/ML [RLD]

Has a generic version of Rebetol been approved?


A generic version of Rebetol has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Rebetol and have been approved by the FDA:


RIBASPHERE (ribavirin capsule; oral)



  • Manufacturer: THREE RIVERS PHARMS

    Approval date: April 6, 2004

    Strength(s): 200MG [AB]

RIBAVARIN (ribavirin capsule; oral)



  • Manufacturer: AUROBINDO PHARMA

    Approval date: September 17, 2009

    Strength(s): 200MG [AB]

ribavirin capsule; oral



  • Manufacturer: SANDOZ

    Approval date: April 6, 2004

    Strength(s): 200MG [AB]


  • Manufacturer: TEVA

    Approval date: October 4, 2004

    Strength(s): 200MG [AB]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: October 28, 2005

    Strength(s): 200MG [AB]

Note: No generic formulation of the following product is available.


  • ribavirin - solution; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rebetol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
    Patent 6,172,046
    Issued: January 9, 2001
    Inventor(s): Albrecht; Janice K.
    Assignee(s): Schering Corporation
    There is disclosed a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
    Patent expiration dates:

    • September 21, 2017
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • September 21, 2017
      ✓ 
      Patent use: METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS


    • September 21, 2017
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • March 21, 2018
      ✓ 
      Patent use: METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
      ✓ 
      Pediatric exclusivity


    • March 21, 2018
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
      ✓ 
      Pediatric exclusivity




  • Polyethylene glycol modified interferon therapy
    Patent 6,177,074
    Issued: January 23, 2001
    Inventor(s): Glue; Paul & Cutler; David L. & Affrime; Melton B.
    Assignee(s): Schering Corporation
    A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.
    Patent expiration dates:

    • November 1, 2016
      ✓ 
      Patent use: METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN


    • November 1, 2016
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • May 1, 2017
      ✓ 
      Patent use: METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
      ✓ 
      Pediatric exclusivity


    • May 1, 2017
      ✓ 
      Pediatric exclusivity




  • Continuous low-dose cytokine infusion therapy
    Patent 6,461,605
    Issued: October 8, 2002
    Inventor(s): David L.; Cutler & Melton B.; Affrime
    Assignee(s): Schering Corporation
    A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein the undesirable side effects normally associated with cytokine administration are diminished or eliminated. The method comprises continuously administering a low dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine. In a preferred embodiment of the invention, chronic hepatitis C is treated by administering a low dose amount of interferon.
    Patent expiration dates:

    • November 1, 2016
      ✓ 
      Patent use: METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B


    • November 1, 2016
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • November 1, 2016
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • May 1, 2017
      ✓ 
      Patent use: METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
      ✓ 
      Pediatric exclusivity


    • May 1, 2017
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
      ✓ 
      Pediatric exclusivity




  • Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
    Patent 6,472,373
    Issued: October 29, 2002
    Inventor(s): Janice K.; Albrecht
    Assignee(s): Schering Corporation
    Methods for treating an antiviral treatment naive patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving administering a therapeutically effective amount of a combination therapy of ribavirin and interferon-alpha for a time period of from 20 up to 50 weeks are disclosed.
    Patent expiration dates:

    • September 21, 2017
      ✓ 
      Patent use: METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY


    • September 21, 2017
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • September 21, 2017
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • March 21, 2018
      ✓ 
      Patent use: METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
      ✓ 
      Pediatric exclusivity


    • March 21, 2018
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
      ✓ 
      Pediatric exclusivity




  • Polyethylene glycol modified interferon therapy
    Patent 6,524,570
    Issued: February 25, 2003
    Inventor(s): Paul; Glue & David L.; Cutler & Melton B.; Affrime
    Assignee(s): Schering Corporation
    A method comprising administering a PEG12000-IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.
    Patent expiration dates:

    • November 1, 2016
      ✓ 
      Patent use: METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION


    • November 1, 2016
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C


    • May 1, 2017
      ✓ 
      Patent use: METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
      ✓ 
      Pediatric exclusivity


    • May 1, 2017
      ✓ 
      Pediatric exclusivity




  • Ribavirin syrup formulations
    Patent 6,790,837
    Issued: September 14, 2004
    Inventor(s): Susan K.; Heimbecher & Joel A.; Sequeira
    Assignee(s): Schering Corporation
    A liquid formulation comprising ribavirin having a longer shelf life and improved taste is disclosed.
    Patent expiration dates:

    • April 5, 2023
      ✓ 
      Drug product


    • October 5, 2023
      ✓ 
      Patent use: METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 29, 2010 - ORPHAN DRUG EXCLUSIVITY

    • January 29, 2011 - PEDIATRIC EXCLUSIVITY

See also...

  • Rebetol Consumer Information (Drugs.com)
  • Rebetol Consumer Information (Wolters Kluwer)
  • Rebetol Solution Consumer Information (Wolters Kluwer)
  • Rebetol Consumer Information (Cerner Multum)
  • Rebetol Advanced Consumer Information (Micromedex)
  • Ribavirin Consumer Information (Wolters Kluwer)
  • Ribavirin Capsules Consumer Information (Wolters Kluwer)
  • Ribavirin Solution Consumer Information (Wolters Kluwer)
  • Ribavirin Consumer Information (Cerner Multum)
  • Ribasphere Ribapak Advanced Consumer Information (Micromedex)
  • Ribavirin Advanced Consumer Information (Micromedex)
  • Ribavirin Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
  • Ribavirin AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Monday, August 3, 2009

Freka-cid




Freka-cid may be available in the countries listed below.


Ingredient matches for Freka-cid



Povidone Iodine

Povidone-Iodine is reported as an ingredient of Freka-cid in the following countries:


  • Hong Kong

International Drug Name Search

Posted by at No comments:
Labels:

Sunday, August 2, 2009

Virgocilline




Virgocilline may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Virgocilline



Colistin Sulfate

Colistin sulfate (a derivative of Colistin) is reported as an ingredient of Virgocilline in the following countries:


  • France

International Drug Name Search

Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)